Increased serum cell-free DNA levels in relation to inflammation are predictive of distant metastasis of esophageal squamous cell carcinoma

Experimental and Therapeutic Medicine

Volumn 1, Issue 1, 2010, Pages 89-92

  Totomochika, Shinobu ^a   Iizuka, Norio ^a   Watanabe, Yusaku ^a   Tsutsui, Masahito ^a   Takeda, Shigeru ^a   Yoshino, Shigefumi ^a   Ichihara, Kiyoshi ^a   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell free DNA; Esophageal squamous cell carcinoma; Prognosis; Real time pcr; Serum

Indexed keywords

C REACTIVE PROTEIN; CYTOKERATIN 19 FRAGMENT; DNA; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HOST; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; PREDICTION; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 77955760474     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000016     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics. CA Cancer J Clin 55: 74-108, 2005.
2. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003.
3. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, IizukaNN, Hazama S, Hirazawa K, Hayashi H, Tangoku A, HiroseKK, Ishihara T and Suzuki T: Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56: 2776-2780, 1996.
4. Iizuka N, Hirose K, Noma T, Hazama S, Tangoku A, HayashiHH, Abe T, Yamamoto K and Oka M: The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma. Br J Cancer 81: 469-475, 1999.
5. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, MutoMM, Ogino T and Yoshida S: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21: 2697-2702, 2003.
6. Kleinberg L and Forastiere AA: Chemoradiation in the management of esophageal cancer. J Clin Oncol 25: 4110-4117, 2007.
7. Chen G, Wang Z, Liu XY, Zhang MY and Liu FY: Abdominal lymph node metastasis in patients with mid thoracic esophageal squamous cell carcinoma. World J Surg 33: 278-283, 2009.
8. Shimada H, Okazumi S, Matsubara H, Nabeya Y, Shiratori T, Shimizu T, Shuto K, Hayashi H and Ochiai T: Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg 30: 1441-1449, 2006.
9. Montesano R, Hollstein M and Hainaut P: Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 3: 225-235, 1996.
10. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
11. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, ChasseEE, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA and Ziegler A: Circulating deoxyribonucleic acid as prognostic marker in non-small cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22: 4157-4164, 2004.
12. Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T and Oka M: Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 97: 1399-1403, 2007.
13. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S and Hoon DS: Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24: 4270-4276, 2006.
14. Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, Ikoma H, Fujiwara H, Kikuchi S, Okamoto K, Ochiai T and Otsuji E: Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res 27: 2737-2741, 2007.
15. Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. 6th edition. UICC, Wiley-Liss, pp81-83, 2002.
16. Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T and Oka M: Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 26: 4713-4719, 2006.
17. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
18. Iida M, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Tokuhisa Y, Sakamoto K, Tamesa T, Miyamoto T, Hamamoto Y and Oka M: Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma Oncol Rep 20: 761-765, 2008.
19. Barak V, Goike H, Panaretakis KW and Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin Biochem 37: 529-540, 2004.
20. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T and Suzuki T: CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 79: 1647-1655, 1997.
21. Brockmann JG, St Nottberg H, Glodny B, Heinecke A and Senninger NJ: CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 6: 4249-4252, 2000.